DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSĀ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving lif
Related Questions
How does the Q2 revenue composition (e.g., collaboration revenue, grant funding, licensing) compare to prior quarters?
Did the company disclose any new partnership, licensing, or collaboration agreements that could affect future revenue streams?
What guidance, if any, was provided for the upcoming 2025ā2027 pipeline timeline and expected regulatory milestones?
Are there any material changes to the capital structure (e.g., stock issuances, debt financings, share buyābacks) disclosed in the update?
What is the current status of the lead geneāediting programs and their potential market size compared to competitors (e.g., CRISPR, Editas)?
What guidance, if any, is provided for upcoming clinical trial milestones (e.g., IND filing, Phase 1/2 data) for the ARCUSĀ® platform?
Are there any updates on the company's cash runway and burn rate, and how does that affect liquidity and potential dilutive financing?
How will the Q2 2025 earnings and guidance compare to consensus analyst estimates?
How does Precision BioSciencesā valuation metrics (e.g., EV/Revenue, P/E, price/cashāburn) compare to peer companies in the geneāediting space?
What are the potential shortāterm catalysts (e.g., data releases, FDA meetings) that could move the stock after the August 7 announcement?